Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration

Published: Tuesday, June 15, 2010
Last Updated: Tuesday, June 15, 2010
Bookmark and Share
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.

The Structural Genomics Consortium (SGC) and Pfizer have announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors – "chemical probes" – for proteins involved in epigenetic signalling.

Pfizer and GlaxoSmithKline (GSK) are now members of this collaboration, launched in late 2008 with the aim to provide the community with high quality research reagents, free from restriction on use.

Globally the collaboration includes the three SGC laboratories in Oxford, Toronto and Stockholm, the National Institutes of Health Chemical Genomics Center in Bethesda, the Departments of Chemistry and Biochemistry at the University of Oxford, the Department of Chemistry at Umea University and a number of additional collaborators in academia.

The program has been awarded a total of US $15M in grant support from the Wellcome Trust, the Ontario Ministry of Research and Innovation in Canada and the Swedish Foundation for Strategic Research to support activities in the UK, Canada and Sweden, respectively.

The collaboration aims to develop small molecules that can stimulate or block the activity of proteins involved in epigenetic control. The study of epigenetics addresses heritable changes in gene function that occur without a change in the DNA sequence. Alterations in these processes are linked to many common diseases, and there is a strong belief that a better understanding of epigenetics could eventually lead to treatments for diseases such as cancer, diabetes, obesity and many psychiatric diseases.

Pfizer is joining the program after having formalized an agreement with the University of Oxford, SGC and GSK. Pfizer will, like GSK, provide medicinal chemistry support to the project.

The collaboration is special in that it brings the medicinal chemistry expertise within industry together with the biological expertise within academia to address an emerging area of biology. The ability to add extra industrial members further demonstrates this consortium as a potential working model for pre-competitive interactions between academia and industry within the field of medicinal chemistry.

In keeping with SGC policy, the structure and function of each probe will be made freely available.

Dr Tony Wood, Vice President and Heads of Worldwide Medicinal Chemistry at Pfizer, said: "This collaboration exemplifies our thinking with respect to public-private collaboration that facilitate 'blue sky' research between industry and academia. It is hoped that combining forces in this way will lead to the rapid development and deployment of research tools. This should help us understand the role that this important group of gene families play in human disease and should aid the overarching goal of providing effective medicines to patients."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer, Washington University Announce Collaboration
Pfizer will provide Washington University scientists access to research data on a large array of its pharmaceutical candidates for indications discovery.
Thursday, May 20, 2010
Pfizer Receives FDA Approval for Geodon® Capsules for the Adjunctive Maintenance Treatment of Bipolar Disorder in Adults
Data show Geodon used as an adjunct to Lithium or Valproate Is effective in the maintenance treatment of Bipolar I disorder.
Monday, November 23, 2009
Pfizer Announces Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities
Pfizer will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS.
Thursday, July 30, 2009
Pfizer Launches Global Regenerative Medicine Research Unit
The new independent research unit will provide new generation of regenerative medicines for major medical needs.
Monday, November 17, 2008
Pfizer Report Demonstrates Value of Conducting Virtual Studies of Drug-Drug Interactions
Scientists have used the Simcyp Simulator to predict the extent of drug-drug interactions for maraviroc, which is used in the treatment of HIV.
Thursday, June 12, 2008
Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
Pfizer will continue to fund the research and preclinical development efforts at Renovis through June 30, 2008, to advance small molecule VR1 antagonists toward clinical development.
Tuesday, April 10, 2007
Scientific News
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
New Clue to How Cancer Causes Organ Failure
New findings from a research group at Uppsala University show that the neutrophil, a type of blood cell, plays an important role in the process of induced organ failure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!